Global Rheumatology Treatment Market
Global rheumatology market was valued at $31bn in 2015 and is forecast to grow at a modest 4.0% CAGR between 2015 and 2024 to reach 2024 global sales of $46bn.
Rheumatology encompasses numerous musculoskeletal and autoimmune diseases that cause systemic manifestations including joint pain, inflammation and destruction. Worldwide, over 470 million people suffer from rheumatologic diseases. Rheumatology represents a significant disease burden with annual costs associated with rheumatologic diseases estimated at $250bn in the U.S.
The four most prevalent rheumatologic diseases are rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), gout, and osteoarthritis (OA).
Rheumatoid arthritis (RA) represents the largest segment within the rheumatology category. Initial therapy in RA includes NSAIDs, methotrexate with physicians turning to TNF-inhibitors to those who are refractory to these treatments. The leading brands within TNF inhibitors include Amgen/Pfizer’s Enbrel, AbbVie’s Humira, J&J’s Remicade J&J/Merck’s Simponi and UCB’s Cimzia.
TNF-inhibitors from AbbVie (Humira), Amgen/Pfizer (Enbrel) and J&J’s Remicade led the rheumatology category during 2015. Bristol Myer’s Orencia, Roche’s Actemra, and Biogen/Roche’s Rituxan are used in RA patients’ refractory to TNF-inhibitors. This may represent a small patient population yet constitutes a multi-billion dollar market.